Patents by Inventor Andrew R. Raubitschek

Andrew R. Raubitschek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4897466
    Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.
    Type: Grant
    Filed: June 6, 1986
    Date of Patent: January 30, 1990
    Assignee: Cetus Corporation
    Inventors: James W. Larrick, Andrew R. Raubitschek, Kenneth E. Truitt
  • Patent number: 4764465
    Abstract: A human monoclonal antibody that directly agglutinates type A human red blood cells is described. The exemplified antibody is an IgM and is produced by hybrid cells lines S-H22 and HHA1. The antibody is useful as an ABO typing reagent.
    Type: Grant
    Filed: September 30, 1986
    Date of Patent: August 16, 1988
    Assignees: Cetus Corporation, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Steven K. H. Foung, Andrew R. Raubitschek, Edgar G. Engleman, F. Carl Grumet, James W. Larrick
  • Patent number: 4624921
    Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.
    Type: Grant
    Filed: April 26, 1984
    Date of Patent: November 25, 1986
    Assignee: Cetus Corporation
    Inventors: James W. Larrick, Andrew R. Raubitschek, Kenneth E. Truitt